
A review of gonococcal surveillance data suggests doxycycline post-exposure prophylaxis (doxyPEP) is unlikely to protect against gonorrhea infection in certain countries because of high tetracycline resistance, researchers reported today in the Journal of Antimicrobial Chemotherapy.
For the study, a team led by researchers from the World Health Organization (WHO) analyzed tetracycline resistance in Neisseria gonorrhoeae isolates collected from 2021 through 2024 in eight countries that participate in the WHO Enhanced Global Gonococcal Antimicrobial Surveillance Programme (WHO EGASP). While doxycycline hasn't been used to treat gonorrhea infections in decades, there are concerns that high levels of tetracycline resistance might limit the effectiveness of doxyPEP against gonorrhea infection. The eight countries included in the analysis were Cambodia, Indonesia, Malawi, the Philippines, South Africa, Thailand, Uganda, and Vietnam.
'Exceedingly high' levels of resistance
Using tetracycline resistance breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and by the Clinical Laboratory and Standards Institute (CLSI), the researchers found that the average tetracycline resistance in the eight countries was 92.2% (83.5% to 100%) and 80.6% (66.3% to 98.6%), respectively. Using a previous minocycline-PEP resistance breakpoint and a breakpoint for high-level plasmid-mediated tetracycline resistance, the tetracycline resistance was 77.3% (47.4% to 98.6%) and 74.3% (31.3% to 98.6%), respectively.
"The exceedingly high levels of gonococcal tetracycline resistance in the eight WHO EGASP countries elucidate that doxycycline-PEP will unlikely significantly reduce the gonorrhoea cases in these countries," the study authors write. "Furthermore, doxycycline-PEP might rapidly select for additional gonococcal strains with tetracycline resistance (low-level and high-level) and MDR and XDR [multidrug-resistant and extensively drug-resistant] strains, i.e. because these strains are mostly resistant to tetracycline."
The authors add that while doxyPEP has been shown to significantly reduce the number of chlamydia and syphilis infections, the benefits will need to be balanced against the potential harms of tetracycline resistance in N gonorrhoeae and other non-sexually transmitted pathogenic and commensal bacteria and alterations of the human microbiome.
"Dissemination of current evidence regarding benefits, risks, limitations, and unknowns concerning mid-term and long-term effects of doxycycline-PEP to community and medical staff is imperative," they conclude.